Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR…
Phase 1 trial shows 90 per cent recurrence-free survival and 90 per cent complete response in patients with high-risk and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
European Society for Medical Oncology
Amgen says Lumakras cuts risk of lung cancer progression by 34 per cent
The medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13 per cent of non-small cell…